Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022 One-year ROMAN follow-up data presented at 2022 American Society f

Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

Company on track to submit NDA to U.S. FDA for avasopasem by end of 2022

One-year ROMAN follow-up data presented at 2022 American

Society for Radiation Oncology (ASTRO)

Annual Meeting showed tumor outcomes and overall survival maintained compared to placebo

One-year ROMAN follow-up data also showed

cisplatin-related chronic kidney disease reduced by 50% in

avasopasem patients compared to placebo

Meta-analysis of both randomized placebo-controlled trials of avasopasem (ROMAN and GT-201) further

underscores efficacy across all key SOM endpoints

MALVERN, Pa. November 9, 2022 Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company

focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the third quarter ended September 30, 2022 and provided

recent corporate updates.

During the quarter, we added to the package of data supporting our planned avasopasem New Drug Application in

radiotherapy-induced severe oral mucositis, which we are on track to submit by the end of the year, said Mel Sorensen, M.D., Galera s President and CEO. We presented long-term follow-up data

from ROMAN at ASTRO, the major annual radiation oncology conference, affirming what we saw in GT-201, specifically that avasopasem reduced severe oral mucositis while maintaining the clinical benefit of

radiation therapy. Moreover, patients were also evaluated for renal function during the one-year follow-up period, and the data showed a 50% reduction in chronic kidney

disease, a known cisplatin-related superoxide toxicity.

Dr. Sorensen continued: Our market research continues to indicate that radiation

and medical oncologists treating head and neck cancer view the avasopasem profile favorably and that the majority would prescribe avasopasem if approved by the FDA. The research also indicates that physicians view SOM the most burdensome side

effect of radiation therapy for head and neck cancer as something best characterized by several key measures. These include not only whether a patient develops SOM, but also how long they suffer from it, when it first develops and whether it

worsens into the most severe grade, Grade 4 OM. The meta-analysis of the already positive results from both the ROMAN and GT-201 trials, underscores that avasopasem improves SOM across these measures.

Recent Corporate Updates

Radiotherapy-Induced Toxicity Programs:

Oral Mucositis (SOM)

Anti-Cancer Programs:

Locally Advanced Pancreatic Cancer (LAPC)

Non-Small Cell Lung Cancer (NSCLC)

General Corporate Updates:

Third Quarter 2022 Financial Highlights

About Galera Therapeutics

Galera Therapeutics, Inc. is a

clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer. Galera s selective dismutase mimetic product

candidate avasopasem manganese (avasopasem, or GC4419) is being evaluated for radiotherapy-induced toxicities. The Company s second product candidate, rucosopasem manganese (rucosopasem, or GC4711), is in clinical-stage development to augment

the anti-cancer efficacy of stereotactic body radiation therapy in patients with non-small cell lung cancer and locally advanced pancreatic cancer. Galera is headquartered in Malvern, PA. For more information,

please visit www.galeratx.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in

this press release that do not relate to matters of historical fact should be considered forward-looking statements, including without limitation statements regarding: the expectations surrounding the continued advancement of Galera s product

pipeline; the potential safety and efficacy of Galera s product candidates and their regulatory and clinical development; the timing of the submission of an NDA for avasopasem for radiotherapy-induced SOM in patients with locally advanced head

and neck cancer with the FDA; the ability of avasopasem to reduce SOM while maintaining the clinical benefit of radiation therapy; the ability of avasopasem to reduce the incidence of CKD; the expectations surrounding the progress of the Phase 2b

trial of rucosopasem in patients with LAPC and the timing of completion of enrollment of the trial; the expectations surrounding the progress of the Phase 1/2 trial of rucosopasem in patients with NSCLC and the timing of completion of enrollment of

the trial; the Company s ability to achieve its goal of transforming radiotherapy in cancer treatment with its selective dismutase mimetics; the potential of GC4711 to augment the anti-cancer efficacy of SBRT in patients with NSCLC and LAPC;

and the Company s ability to fund its operating expenses and capital expenditure into the second half of 2023. These forward-looking statements are based on management s current expectations. These statements are neither promises nor

guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause Galera s actual results, performance or achievements to be materially different from any future results, performance or achievements

expressed or implied by the forward-looking statements, including, but not limited to, the following: Galera s limited operating history; anticipating continued losses for the foreseeable future; substantial doubt regarding our ability to

continue as a going concern; needing substantial funding and the ability to raise capital; Galera s dependence on avasopasem manganese (GC4419); uncertainties inherent in the conduct of clinical trials; difficulties or delays enrolling patients

in clinical trials; the FDA s acceptance of data from clinical trials outside the United States; undesirable side effects from Galera s product candidates; risks relating to the regulatory approval process; failure to capitalize on more

profitable product candidates or indications; ability to receive or maintain Breakthrough Therapy Designation or Fast Track Designation for product candidates; failure to obtain regulatory approval of product candidates in the United States or other

jurisdictions; ongoing regulatory obligations and continued regulatory review; risks related to commercialization; risks related to competition; ability to retain key employees and manage growth; risks related to intellectual property; inability to

maintain collaborations or the failure of these collaborations; Galera s reliance on third parties; the possibility of system failures or security breaches; liability related to the privacy of health information obtained from clinical trials

and product liability lawsuits; unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives; environmental, health and safety laws and regulations; the impact of the

COVID-19 pandemic on Galera s business and operations, including preclinical studies and clinical trials, and general economic conditions; risks related to ownership of Galera s common stock; the

possibility of Galera s common stock being delisted from The Nasdaq Global Market; and significant costs as a result of operating as a public company. These and other important factors discussed under the caption Risk Factors in

Galera s Annual Report on Form 10-K for the year ended December 31, 2021 and Quarterly Report on Form 10-Q for the quarter ended September 30, 2022 filed

with the U.S. Securities and Exchange Commission (SEC) and Galera s other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any

forward-looking statements speak only as of the date of this press release and are based on information available to Galera as of the date of this release, and Galera assumes no obligation to, and does not intend to, update any forward-looking

statements, whether as a result of new information, future events or otherwise.

Galera Therapeutics, Inc.

Consolidated Statements of Operations

(unaudited, in thousands except share and per share data)

Galera Therapeutics, Inc.

Selected Consolidated Balance Sheet Data

(unaudited, in thousands)

Galera Therapeutics, Inc.

Solebury Strategic Communications

Solebury Strategic Communications